<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Gastrointestinal decontamination of the poisoned patient</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Gastrointestinal decontamination of the poisoned patient</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Gastrointestinal decontamination of the poisoned patient</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Robert G Hendrickson, MD, FACMT, FAACT</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Shana Kusin, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Michele M Burns, MD, MPH</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Michelle Ruha, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Michael Ganetsky, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jun 27, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H18993739"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Gastrointestinal decontamination refers to the practice of functionally removing an ingested toxin from the gastrointestinal (GI) tract in order to decrease its absorption or increase its clearance. Historically, many approaches have been adopted, including gastric evacuation (forced emesis or gastric lavage), intra-gastric binding (most commonly by single or multidose activated charcoal), or speeding transit of toxins to decrease total absorption time (whole bowel irrigation or cathartics). As clinical practice has evolved and understanding of the efficacy, risks, and benefits of decontamination have grown, many practices have fallen out of favor.</p><p>This topic provides an overview of the approach to gastrointestinal decontamination in poisoned patients and a review of the evidence supporting the approach described. The management of intoxication with specific agents and general management of the poisoned patient, including children, are reviewed separately. </p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/324.html" rel="external">"General approach to drug poisoning in adults"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/13850.html" rel="external">"Initial management of the critically ill adult with an unknown overdose"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/6496.html" rel="external">"Approach to the child with occult toxic exposure"</a>.)</p><p></p><p class="headingAnchor" id="H18993746"><span class="h1">APPROACH TO GASTROINTESTINAL DECONTAMINATION</span><span class="headingEndMark"> — </span>No controlled clinical studies have demonstrated that the "routine" use of gastrointestinal (GI) decontamination reduces morbidity and mortality in poisoned patients. However, evidence from human volunteer trials and clinical studies suggest that decontamination may reduce the absorption of toxins in the GI tract and may be helpful in select circumstances [<a href="#rid1">1-4</a>].</p><p>The decision to perform GI decontamination is based upon the specific poison(s) ingested, the time from ingestion to presentation, presenting symptoms, and the predicted severity of poisoning. GI decontamination is most likely to benefit patients who:</p><p class="bulletIndent1"><span class="glyph">●</span>Present for care soon after ingestion (usually within one to two hours)</p><p class="bulletIndent1"><span class="glyph">●</span>Have ingested a poison and amount suspected to cause toxicity</p><p class="bulletIndent1"><span class="glyph">●</span>Do not have clinical factors (eg, obtundation) that make decontamination dangerous</p><p></p><p>GI decontamination should <strong>not</strong> be performed if the agent and amount ingested are clearly nontoxic, if the agent is considered fully absorbed due to delayed presentation, or if the toxin is not amenable to decontamination.</p><p>It is common practice for intentional and potentially toxic ingestions to be treated with activated charcoal (AC) alone. However, in select scenarios other methods of GI decontamination may be useful.</p><p class="headingAnchor" id="H18993753"><span class="h1">METHODS OF DECONTAMINATION</span></p><p class="headingAnchor" id="H18993761"><span class="h2">Activated charcoal</span><span class="headingEndMark"> — </span>Activated charcoal (AC) is a highly adsorbent powder made from superheated, high surface area, porous particles produced by pyrolysis of organic material. Its extensive surface area is covered with a carbon-based network that also includes functional groups (eg, carbonyl, hydroxyl) that adsorb chemicals within minutes of contact, preventing gastrointestinal absorption and subsequent toxicity. Evidence supporting the use of AC is discussed separately.</p><p class="headingAnchor" id="H18993776"><span class="h3">Indications</span><span class="headingEndMark"> — </span>AC is most likely to benefit patients when administered while toxin remains in the stomach. Traditionally, this period is thought to be within one hour of poison ingestion, but the potential for benefit when administered later cannot be excluded [<a href="#rid1">1,4</a>].</p><p class="headingAnchor" id="H18993783"><span class="h3">Contraindications</span><span class="headingEndMark"> — </span>Contraindications to the administration of a single-dose of activated charcoal (SDAC) include:</p><p class="bulletIndent1"><span class="glyph">●</span>Depressed mental status without airway protection (risk of aspiration)</p><p></p><p class="bulletIndent1">The decision to intubate a poisoned patient is often complicated, but it should be made independently of the decision to give AC. In particular, <strong>tracheal intubation should not be performed for the sole purpose of giving AC</strong>.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Late presentation (ie, no toxin is likely to remain in the stomach)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Increased risk and severity of aspiration associated with AC use (eg, hydrocarbon ingestion)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Need for endoscopy (eg, significant caustic ingestion) – AC is likely to impair visibility during endoscopy</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Toxins poorly adsorbed by AC (eg, metals including iron and <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a>, alkali, mineral acids, alcohols)  (<a class="graphic graphic_table graphicRef77553" href="/d/graphic/77553.html" rel="external">table 1</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Presence of intestinal obstruction (absolute contraindication) or concern for decreased peristalsis (relative contraindication)</p><p></p><p class="headingAnchor" id="H18993795"><span class="h3">Dose</span><span class="headingEndMark"> — </span>The optimal dose of SDAC is not known, but available data show a dose-response relationship. In vitro studies suggest an AC:toxin ratio of 10:1 to be effective<sup> </sup>[<a href="#rid5">5</a>]. Alternatively, the following dosing regimen is suggested<sup> </sup>[<a href="#rid1">1</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Children up to one year of age: 10 to 25 g, or 0.5 to 1.0 g/kg</p><p class="bulletIndent1"><span class="glyph">●</span>Children 1 to 12 years of age: 25 to 50 g, or 0.5 to 1.0 g/kg (maximum dose 50 g)</p><p class="bulletIndent1"><span class="glyph">●</span>Adolescents and adults: 25 to 100 g (with 50 g representing the usual adult dose) </p><p></p><p class="headingAnchor" id="H18993802"><span class="h3">Administration</span><span class="headingEndMark"> — </span>AC is available as a powder that is mixed with water to form a slurry. The slurry is gritty and poorly palatable, making administration to children particularly difficult. Flavoring the slurry with juice, cola, chocolate milk, or ice cream may improve compliance but potentially decreases the adsorptive capacity of AC [<a href="#rid6">6,7</a>]. AC is also commercially available as a suspension with thickening agents, such as <a class="drug drug_general" data-topicid="9940" href="/d/drug information/9940.html" rel="external">sorbitol</a>, which may help improve palatability and additionally act as a cathartic<sup> </sup>[<a href="#rid8">8,9</a>].</p><p>Because <a class="drug drug_general" data-topicid="9940" href="/d/drug information/9940.html" rel="external">sorbitol</a> with AC may cause electrolyte imbalances, it is <strong>not</strong> recommended in children. However, if sorbitol-containing AC is the only formulation available, it may be given but only for one dose.</p><p class="headingAnchor" id="H18993809"><span class="h3">Complications</span><span class="headingEndMark"> — </span>The overall rate of AC-associated complications reported in the literature is low<sup> </sup>[<a href="#rid1">1</a>]. Gastrointestinal side effects including fullness, abdominal pain, nausea, vomiting, constipation, and diarrhea have been reported, with higher rates occurring if AC is used in combination with <a class="drug drug_general" data-topicid="9940" href="/d/drug information/9940.html" rel="external">sorbitol</a> [<a href="#rid1">1</a>]. Treatment with sorbitol-containing AC should be avoided in children unless there is no alternative, and if that is the case it must never be used for more than one dose. According to two randomized trials, aspiration occurs in less than one percent of poisonings and is not increased in patients who receive AC [<a href="#rid10">10,11</a>]. Aspiration occurred most often when AC was used in conjunction with gastric emptying techniques that are no longer routinely recommended.</p><p class="headingAnchor" id="H26755739"><span class="h3">Evidence of efficacy and adverse effects</span></p><p class="headingAnchor" id="H26755393"><span class="h4">Activated charcoal: Volunteer data</span><span class="headingEndMark"> — </span>The majority of data supporting the efficacy of activated charcoal (AC) come from in vitro and animal data or volunteer trials. An early study simulating the gastric environment demonstrated that many chemicals adsorb avidly to AC in a dose dependent fashion, but that certain substances – particularly highly ionic compounds with low molecular weight, mineral acids, and strong bases – do not bind well [<a href="#rid12">12</a>]. AC has not been shown to adsorb ethanol, even when administered prior to ethanol ingestion [<a href="#rid13">13</a>].</p><p>A number of volunteer trials support the efficacy of AC when it is administered early after ingestion, with absorption decreased by up to 95 percent or more when AC is administered within five minutes [<a href="#rid14">14,15</a>]. When AC is administered one hour after toxin ingestion, systemic absorption is reduced to the range of 50 to 75 percent, depending upon the toxin [<a href="#rid15">15-18</a>]. Despite the results of these trials, it is important to remember that volunteer scenarios may differ markedly from actual poisonings with respect to the timing of presentation, amount of toxin ingested, and presence of other factors, such as food in the stomach or drugs that alter GI transit times.</p><p>The results of volunteer trials, designed specifically to evaluate the effect of AC when administered later after ingestion, are less compelling. Two volunteer trials failed to find a statistically significant reduction in absorption when AC was administered at two, three, or four hours following ingestion of therapeutic doses of <a class="drug drug_general" data-topicid="9242" href="/d/drug information/9242.html" rel="external">acetaminophen</a> [<a href="#rid19">19,20</a>]. A third trial demonstrated a small but statistically significant reduction in serum acetaminophen levels when AC was given three hours after drug ingestion [<a href="#rid21">21</a>]. The subjects in all three volunteer trials received therapeutic range doses of acetaminophen, so the results are difficult to extrapolate to larger ingestions that occur in poisoned patients. In a trial where volunteers were given slightly supratherapeutic doses of <a class="drug drug_general" data-topicid="9498" href="/d/drug information/9498.html" rel="external">rivaroxaban</a> (40 versus 20 mg maximum recommended dose), AC administered as late as eight hours after ingestion produced a statistically significant decrease in the concentration-time curve [<a href="#rid22">22</a>]. This decrease may reflect the particular pharmacokinetics of rivaroxaban but warrants further study.</p><p class="headingAnchor" id="H26755400"><span class="h4">Activated charcoal: Clinical trials</span><span class="headingEndMark"> — </span>Randomized controlled trials of poisoned patients treated with activated charcoal (AC) have failed to demonstrate a consistent impact on clinically important outcomes. However, this may in part be due to methodologic problems in some studies, such as including treatments with AC given several hours after ingestion and treatment of patients with little or no risk of toxicity.</p><p class="bulletIndent1"><span class="glyph">●</span>A trial of 1479 poisoned patients randomly assigned to receive AC or no decontamination reported higher rates of emesis and intubation, as well as a small but statistically significant increase in emergency department length of stay, in patients treated with AC, but overall no significant differences were noted in the clinical course or rates of aspiration between groups [<a href="#rid23">23</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A trial of 71 patients with an overdose of tricyclic antidepressants (TCA) randomly assigned patients to gastric lavage with or without AC and found no difference in serum drug concentrations between groups [<a href="#rid24">24</a>]. Of note, most patients presented late following ingestion.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A trial of 327 patients, who were randomly assigned to receive AC or no decontamination, found no difference in length of stay, vomiting, aspiration, intubation, or mortality between groups [<a href="#rid10">10</a>]. The authors noted that benzodiazepines, <a class="drug drug_general" data-topicid="9242" href="/d/drug information/9242.html" rel="external">acetaminophen</a>, and selective serotonin reuptake inhibitors (SSRIs) comprised the majority of toxins, and these drugs would generally not be expected to cause severe toxicity regardless of whether GI decontamination were performed.</p><p></p><p>Three observational studies of poisoned patients examined the question of AC efficacy in late-presenting patients:</p><p class="bulletIndent1"><span class="glyph">●</span>A prospective observational series of patients with toxic <a class="drug drug_general" data-topicid="9242" href="/d/drug information/9242.html" rel="external">acetaminophen</a> concentrations who presented more than four hours following ingestion found a lower rate of liver injury among patients given AC in addition to <a class="drug drug_general" data-topicid="9317" href="/d/drug information/9317.html" rel="external">N-acetylcysteine</a> [<a href="#rid25">25</a>]. For patients given AC between four and eight hours after ingestion, the rate of liver injury (AST or ALT &gt;1000 IU/L) was 0 versus 12 percent in the group that did not receive AC. Liver injury rates were also lower for those treated 9 to 12 hours after ingestion (3 versus 52 percent) and 13 to 16 hours after ingestion (10 versus 45 percent).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>An observational study of 200 patients with massive (&gt;40 g) <a class="drug drug_general" data-topicid="9242" href="/d/drug information/9242.html" rel="external">acetaminophen</a> ingestion found that patients who received AC up to four hours after ingestion had a significantly lower "paracetamol ratio" (defined as the ratio of the first acetaminophen concentration compared with the nomogram cutoff at the time of measurement) than those who did not receive AC or received it &gt;4 hours after ingestion (paracetamol ratio 1.4 versus 2.2) [<a href="#rid26">26</a>]. Patients who received AC within four hours also had a significantly lower risk of hepatotoxicity (odds ratio [OR] 0.12), which persisted when adjusted for time to <a class="drug drug_general" data-topicid="9317" href="/d/drug information/9317.html" rel="external">acetylcysteine</a> (OR 0.20). Although it was not a focus of the paper, the presented data suggest that the effect of AC on the paracetamol ratio was similar when given within two hours versus between two and four hours.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A retrospective series described 981 consecutive patients poisoned with <a class="drug drug_general" data-topicid="9242" href="/d/drug information/9242.html" rel="external">acetaminophen</a> who were treated, prior to receiving <a class="drug drug_general" data-topicid="9317" href="/d/drug information/9317.html" rel="external">N-acetylcysteine</a>, with gastric lavage and AC, AC alone, or no decontamination [<a href="#rid27">27</a>]. The authors reported that, in patients presenting within 24 hours with ingestions of 10 g or greater, administration of AC prior to N-acetylcysteine resulted in a lower risk of liver injury (defined AST or ALT greater than 1000 IU/L) compared to treatment with N-acetylcysteine alone (OR 0.36, 95% CI 0.23-0.58) [<a href="#rid27">27</a>]. The authors found that this effect predominates when patients present within two hours, but may extend to many who present as long as three hours later.</p><p></p><p class="headingAnchor" id="H26755407"><span class="h4">Activated charcoal: Adverse effects</span><span class="headingEndMark"> — </span>Aspiration is the concern most often cited when clinicians choose not to administer activated charcoal (AC). In their joint position paper on single-use AC, the American Academy of Clinical Toxicology and the European Association of Poison Centres and Clinical Toxicologists state that charcoal itself is not responsible for aspiration, but rather administering it improperly (ie, to a patient with an inadequately protected airway; in association with lavage; or instilling it directly into the lung via an improperly placed nasogastric tube) [<a href="#rid1">1</a>]. In addition, when aspiration does occur, poor outcomes cannot clearly be attributed to the charcoal itself rather than the aspiration of acidic gastric contents.</p><p>Given the widespread use of AC, the overall rate of adverse effects, particularly aspiration, associated with its administration is low. In a randomized clinical trial of self-poisoned adults, AC was found to increase the risk of vomiting (23 versus 13 percent in controls) [<a href="#rid11">11</a>], but the rate of aspiration was low in both groups (two patients in each group developed aspiration pneumonia out of a total of 1479). A second trial of 327 patients found similar rates of both vomiting (14 and 15 percent, respectively) and aspiration (&lt;1 percent in both groups) in patients treated with AC and those not treated [<a href="#rid10">10</a>].The results of two observational studies suggest that emesis may occur at a higher rate when <a class="drug drug_general" data-topicid="9940" href="/d/drug information/9940.html" rel="external">sorbitol</a> is added to AC [<a href="#rid28">28,29</a>].</p><p>A retrospective chart review of 4562 overdose patients looking for predictors of aspiration found that age, male sex, GCS &lt;15, emesis, seizure, tricyclic antidepressant overdose, and an elapsed time of more than 24 hours between ingestion and presentation were all predictors of aspiration pneumonia, whereas AC administration itself was not [<a href="#rid30">30</a>]. Another retrospective chart review of patients who received AC after intubation found that 2 out of 50, or 4 percent, developed an infiltrate not present prior to intubation [<a href="#rid31">31</a>]; however, the two cases of aspiration pneumonia could not clearly be attributed to charcoal administration.</p><p>Other less important gastrointestinal side effects have been reported. In a volunteer study, constipation and abdominal fullness occurred at a rate of 46 percent, nausea at 18 percent, and vomiting at 8 percent [<a href="#rid21">21</a>]. Constipation occurred in 60 percent of subjects in another volunteer study [<a href="#rid15">15</a>].</p><p class="headingAnchor" id="H18993821"><span class="h2">Multidose activated charcoal</span><span class="headingEndMark"> — </span>In some instances, patients may benefit from the repeated administration of activated charcoal (MDAC). Three distinct mechanisms are thought to account for such benefit:</p><p class="bulletIndent1"><span class="glyph">●</span>Interruption of enterohepatic recirculation</p><p class="bulletIndent1"><span class="glyph">●</span>Facilitation of transluminal diffusion from the body into the bowel lumen (“gut dialysis”), followed by excretion</p><p class="bulletIndent1"><span class="glyph">●</span>Reduced absorption of extended or delayed release formulations</p><p></p><p class="headingAnchor" id="H18993828"><span class="h3">Indications</span><span class="headingEndMark"> — </span>MDAC <strong>may</strong> be helpful in life-threatening ingestions of the following medications, but evidence is limited and opinions among toxicologists vary [<a href="#rid2">2</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Carbamazepine (see  <a class="medical medical_review" href="/d/html/332.html" rel="external">"Carbamazepine poisoning"</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Dapsone</p><p class="bulletIndent1"><span class="glyph">●</span>Phenobarbital</p><p class="bulletIndent1"><span class="glyph">●</span>Quinine</p><p class="bulletIndent1"><span class="glyph">●</span>Theophylline<sup> </sup>(see  <a class="medical medical_review" href="/d/html/6501.html" rel="external">"Theophylline poisoning"</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Caffeine (see  <a class="medical medical_review" href="/d/html/139562.html" rel="external">"Acute caffeine poisoning"</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Acetylsalicylic acid (aspirin) (see  <a class="medical medical_review" href="/d/html/329.html" rel="external">"Salicylate (aspirin) poisoning: Clinical manifestations and evaluation"</a> and  <a class="medical medical_review" href="/d/html/140354.html" rel="external">"Salicylate (aspirin) poisoning: Management"</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Phenytoin (see  <a class="medical medical_review" href="/d/html/312.html" rel="external">"Phenytoin poisoning"</a>)</p><p></p><p>Volunteer and animal data suggest that MDAC increases elimination of several toxins (eg, <a class="drug drug_general" data-topicid="8605" href="/d/drug information/8605.html" rel="external">amitriptyline</a>, <a class="drug drug_general" data-topicid="9360" href="/d/drug information/9360.html" rel="external">digoxin</a>, <a class="drug drug_general" data-topicid="9378" href="/d/drug information/9378.html" rel="external">disopyramide</a>, <a class="drug drug_general" data-topicid="9672" href="/d/drug information/9672.html" rel="external">nadolol</a>, <a class="drug drug_general" data-topicid="9781" href="/d/drug information/9781.html" rel="external">piroxicam</a>), but clinical data are currently insufficient to support the routine use of MDAC in these exposures<sup> </sup>[<a href="#rid2">2</a>].</p><p class="headingAnchor" id="H18993835"><span class="h3">Contraindications</span><span class="headingEndMark"> — </span>Contraindications to the use of MDAC are similar to those of SDAC, but also include:</p><p class="bulletIndent1"><span class="glyph">●</span>Presence of intestinal obstruction (absolute) or concern for decreased peristalsis (relative)</p><p></p><p class="headingAnchor" id="H18993842"><span class="h3">Dose</span><span class="headingEndMark"> — </span>An optimal dosing regimen for MDAC has not been established. In general, after the initial dose, AC should be administered at a rate of at least 12.5 g/hour, or the equivalent, given as divided doses. Examples of acceptable regimens include 50 g administered every four hours, or 25 g every two hours. A volunteer study found no difference in effectiveness of larger doses spread out over time compared to smaller, more frequent doses<sup> </sup>[<a href="#rid32">32</a>].</p><p class="headingAnchor" id="H18993853"><span class="h3">Administration</span><span class="headingEndMark"> — </span>Administration is similar to that of AC, but the concurrent use of a cathartic, such as <a class="drug drug_general" data-topicid="9940" href="/d/drug information/9940.html" rel="external">sorbitol</a> is <strong>not</strong> recommended. This is of particular importance with young children, in whom the development of diarrhea may lead to dangerous fluid shifts and electrolyte imbalance<sup> </sup>[<a href="#rid2">2</a>].</p><p class="headingAnchor" id="H18993860"><span class="h3">Complications</span><span class="headingEndMark"> — </span>In addition to the complications associated with single-dose AC, constipation and bowel obstruction have been reported.</p><p class="headingAnchor" id="H26755899"><span class="h3">Evidence of efficacy and adverse effects</span><span class="headingEndMark"> — </span>Volunteer trials of MDAC have found significant decreases in the elimination half-life of several drugs, including <a class="drug drug_general" data-topicid="9769" href="/d/drug information/9769.html" rel="external">phenytoin</a>, <a class="drug drug_general" data-topicid="9711" href="/d/drug information/9711.html" rel="external">nortriptyline</a>, <a class="drug drug_general" data-topicid="8620" href="/d/drug information/8620.html" rel="external">aminophylline</a>, <a class="drug drug_general" data-topicid="9763" href="/d/drug information/9763.html" rel="external">phenobarbital</a>, <a class="drug drug_general" data-topicid="9198" href="/d/drug information/9198.html" rel="external">carbamazepine</a>, phenylbutazone, <a class="drug drug_general" data-topicid="9360" href="/d/drug information/9360.html" rel="external">digoxin</a>, and <a class="drug drug_general" data-topicid="9324" href="/d/drug information/9324.html" rel="external">dapsone</a> [<a href="#rid15">15,17,32-36</a>]. However, the results of clinical trials have been mixed:</p><p class="bulletIndent1"><span class="glyph">●</span>A randomized controlled trial of 4629 poisoned patients comparing the routine use of MDAC to single-dose AC or no intervention found no difference in rates of intubation, toxin-specific clinical effects, or mortality among groups [<a href="#rid37">37</a>]. The trial was limited by the prolonged time to treatment for many patients and lower than expected mortality in the control group.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In contrast, a randomized controlled trial of 401 patients poisoned with yellow oleander-poisoned and treated with either MDAC or a single dose of AC found lower rates of mortality and ICU admission among the MDAC group [<a href="#rid38">38</a>]. This study differs from the larger trial described above in the narrow scope of toxin studied, shorter time to treatment, and longer administration of MDAC (along with better adherence to the regimen).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Another randomized trial comparing the use of MDAC with no intervention in patients with <a class="drug drug_general" data-topicid="9769" href="/d/drug information/9769.html" rel="external">phenytoin</a> overdose found a statistically significant decrease in the time to reach a sub-toxic concentration among those treated, but the study was limited by small sample size (17 patients) and baseline differences in phenytoin concentrations between groups [<a href="#rid36">36</a>].</p><p></p><p>The paucity of data supporting the efficacy of MDAC in actual poisonings and the availability of better treatments for some of the agents studied (eg, antibody [Fab] fragments for <a class="drug drug_general" data-topicid="9360" href="/d/drug information/9360.html" rel="external">digoxin</a> overdose) have informed the joint position statement of the American Academy of Clinical Toxicology and the European Association of Poison Centres and Clinical Toxicologists, which only supports the use of MDAC in life-threatening ingestions of <a class="drug drug_general" data-topicid="9198" href="/d/drug information/9198.html" rel="external">carbamazepine</a>, <a class="drug drug_general" data-topicid="9324" href="/d/drug information/9324.html" rel="external">dapsone</a>, <a class="drug drug_general" data-topicid="9763" href="/d/drug information/9763.html" rel="external">phenobarbital</a>, <a class="drug drug_general" data-topicid="9847" href="/d/drug information/9847.html" rel="external">quinine</a>, or <a class="drug drug_general" data-topicid="10281" href="/d/drug information/10281.html" rel="external">theophylline</a> [<a href="#rid2">2</a>].</p><p>Complications of MDAC administration are similar to those associated with single-dose AC and are described separately. (See <a class="local">'Activated charcoal: Adverse effects'</a> above.)</p><p>Additional concerns specific to the repeated administration of AC include the development of an ileus or obstruction. There are published reports of patients developing a bowel obstruction requiring surgical intervention and even bowel perforation following repeated administration of AC [<a href="#rid39">39-41</a>]. However, the large randomized trial described above did not report any such complications [<a href="#rid37">37</a>].</p><p class="headingAnchor" id="H18993876"><span class="h2">Whole bowel irrigation</span><span class="headingEndMark"> — </span>Whole bowel irrigation<strong> </strong>(WBI) refers to the administration of osmotically balanced polyethylene glycol electrolyte solution (PEG-ES) to induce liquid stool and mechanically flush pills, tablets, or drug packets from the GI tract.</p><p class="headingAnchor" id="H18993883"><span class="h3">Indications</span><span class="headingEndMark"> — </span>WBI is not routinely recommended, but it may be helpful in the following settings [<a href="#rid3">3</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Potentially toxic ingestions of sustained-release or enteric coated pill formulations</p><p class="bulletIndent1"><span class="glyph">●</span>Significant ingestions of toxins not adsorbed by activated charcoal (eg, iron tablets, lead-containing foreign bodies)</p><p class="bulletIndent1"><span class="glyph">●</span>Ingestion of illicit drug packets (see  <a class="medical medical_review" href="/d/html/327.html" rel="external">"Internal concealment of drugs of abuse (body packing)"</a>)</p><p></p><p class="headingAnchor" id="H18993890"><span class="h3">Contraindications</span><span class="headingEndMark"> — </span>Contraindications to WBI include:</p><p class="bulletIndent1"><span class="glyph">●</span>Ileus, bowel obstruction, or intestinal perforation</p><p class="bulletIndent1"><span class="glyph">●</span>Clinically significant GI hemorrhage</p><p class="bulletIndent1"><span class="glyph">●</span>Hemodynamic instability (concern for sequestration of bowel and worsening of shock)</p><p class="bulletIndent1"><span class="glyph">●</span>Intractable emesis</p><p></p><p class="headingAnchor" id="H18993897"><span class="h3">Dose</span><span class="headingEndMark"> — </span>There are no dose-response studies for WBI, but a consensus recommendation regarding dosing is as follows<sup> </sup>[<a href="#rid3">3</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Children 9 months to 6 years: 500 mL/hr</p><p class="bulletIndent1"><span class="glyph">●</span>Children 6 to 12 years: 1000 mL/hr</p><p class="bulletIndent1"><span class="glyph">●</span>Adolescents and adults: 1500 to 2000 mL/hr</p><p></p><p>WBI is continued until the rectal effluent is clear. Radiographic studies may be useful in some circumstances (eg, iron ingestion, body packing) to confirm the absence of residual toxin.</p><p class="headingAnchor" id="H18993904"><span class="h3">Administration</span><span class="headingEndMark"> — </span>Most patients tolerate poorly the large volume of fluid that must be taken orally to effectively perform WBI. In many cases, nasogastric tube placement is necessary for PEG-ES administration.</p><p class="headingAnchor" id="H18993911"><span class="h3">Complications</span><span class="headingEndMark"> — </span>There is a paucity of published data regarding complications associated with WBI. GI complaints including nausea, vomiting, cramping, and bloating are relatively common<sup> </sup>[<a href="#rid3">3,42</a>]. Patients with vomiting and an unprotected airway are at risk of aspiration, but this has not been reported as a direct result of WBI.</p><p class="headingAnchor" id="H26756209"><span class="h3">Evidence of efficacy and adverse effects</span><span class="headingEndMark"> — </span>Whole bowel irrigation (WBI) may be useful for patients who have ingested extended-release or enteric-coated tablets, particularly when patients present more than two hours after ingestion and therefore are not likely to benefit from charcoal administration. Volunteer data suggest that WBI is effective in some cases, but may interfere with activated charcoal (AC) when administered concurrently [<a href="#rid16">16</a>]. As an example, the results of an in vitro study suggest that PEG-ES may increase the dissolution of non-sustained-release <a class="drug drug_general" data-topicid="9242" href="/d/drug information/9242.html" rel="external">acetaminophen</a> tablets, exacerbating poisoning [<a href="#rid43">43</a>].</p><p>One volunteer study examining the effect of WBI on extended release <a class="drug drug_general" data-topicid="9242" href="/d/drug information/9242.html" rel="external">acetaminophen</a> absorption as well as the transit time of radiopaque markers found that WBI did not significantly reduce systemic drug absorption but did lead to a clustering of markers in the right hemicolon in the majority of test subjects [<a href="#rid44">44</a>]. The significance of the latter finding remains unclear.</p><p>One retrospective cohort study of acute-on-chronic <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a> exposures found that early decontamination with sodium polystyrene and WBI was associated with lower Poison Severity Scores (PSS) (OR 0.21; 0.04-0.99), but was underpowered to detect a difference in PSS with WBI alone [<a href="#rid45">45</a>].</p><p>There is a dearth of high quality evidence supporting the use of WBI, with case series comprising the majority of studies [<a href="#rid3">3</a>]. In one study, statistical analysis of blood concentrations of 71 patients poisoned with extended-release <a class="drug drug_general" data-topicid="10042" href="/d/drug information/10042.html" rel="external">venlafaxine</a> found that WBI, when administered with AC, reduced the total absorbed fraction of drug by 29 percent [<a href="#rid46">46</a>].</p><p class="headingAnchor" id="H18993923"><span class="h2">Gastric lavage</span><span class="headingEndMark"> — </span>Gastric lavage<strong> </strong>(GL) refers to the passage of a large bore orogastric tube followed by repetitive instillation and aspiration of small aliquots of fluid in an attempt to aspirate pill fragments or other toxins from within the stomach. Referred to as “stomach pumping” by the lay public, this formerly widespread modality has been largely abandoned due to unclear benefit (particularly when compared with other readily available and less invasive techniques) and the risk of serious complications.</p><p class="headingAnchor" id="H18993937"><span class="h3">Indications</span><span class="headingEndMark"> — </span>The American Association of Poison Centers (AAPC) and the European Association of Poisons Centres and Clinical Toxicologists (EAPCCT) have issued a joint statement that gastric lavage should not be employed routinely, if ever, in the management of poisoned patients<sup> </sup>[<a href="#rid47">47</a>]. A survey of regional hospitals in the southeast United States suggested that many institutions are no longer stocking supplies for GL, and practitioners are performing it less often [<a href="#rid48">48</a>]. However, there are rare cases (eg, recent and potentially lethal ingestion) where the procedure may be considered after carefully weighing the well-documented risks against the unclear benefits.</p><p class="headingAnchor" id="H18993930"><span class="h3">Contraindications</span><span class="headingEndMark"> — </span>GL is contraindicated in the following cases:</p><p class="bulletIndent1"><span class="glyph">●</span>Unprotected airway</p><p class="bulletIndent1"><span class="glyph">●</span>Caustic ingestion (due to risk of exacerbating any esophageal or gastric injury)</p><p class="bulletIndent1"><span class="glyph">●</span>Hydrocarbon ingestion (due to high aspiration risk)</p><p class="bulletIndent1"><span class="glyph">●</span>Patients at risk of GI hemorrhage or perforation (recent surgery, underlying anatomic abnormality or pathology, coagulopathy)</p><p></p><p class="headingAnchor" id="H18993944"><span class="h3">Complications</span><span class="headingEndMark"> — </span>Complications associated with GL are significant and include the following: aspiration pneumonia, esophageal or gastric perforation, laryngospasm, hypoxia, dysrhythmia, and fluid or electrolyte imbalance [<a href="#rid47">47</a>]. GL may also propel toxins that were to be removed past the pylorus, potentially facilitating systemic absorption and decreasing the effectiveness of activated charcoal<sup> </sup>[<a href="#rid49">49</a>].</p><p class="headingAnchor" id="H26756451"><span class="h3">Evidence of efficacy and adverse effects</span><span class="headingEndMark"> — </span>Gastric lavage (GL), once a mainstay of emergency decontamination of poisoned patients, has been largely abandoned due to the effectiveness of activated charcoal (AC).</p><p>The results of multiple studies call into question the effectiveness of GL:</p><p class="bulletIndent1"><span class="glyph">●</span>A randomized trial of self-poisoned patients reported that 52 percent of radio opaque tablets the patients had been asked to swallow immediately prior to GL were retained in the GI tract, while 33 percent were propelled forward into the small bowel [<a href="#rid49">49</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a study of poisoned patients, endoscopy performed immediately following gastric emptying revealed that 15 of 17 patients treated with GL (88 percent) had residual intragastric solid [<a href="#rid50">50</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A volunteer study found that only 45 percent of ingested cobalt was recovered using GL [<a href="#rid51">51</a>].</p><p></p><p>When compared directly to AC or when used in conjunction with AC, GL generally does not provide added benefit according to the results of volunteer and clinical trials. Representative studies include the following:</p><p class="bulletIndent1"><span class="glyph">●</span>In a randomized controlled trial of 808 poisoned patients, symptomatic patients treated with gastric emptying (either ipecac or gastric lavage) had a fourfold increase in intubation rates and a two-fold increase in the rate of ICU admission compared to those receiving AC [<a href="#rid23">23</a>]. GL was associated with a significantly increased risk of aspiration pneumonia.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>An observational study of 981 consecutive patients poisoned with <a class="drug drug_general" data-topicid="9242" href="/d/drug information/9242.html" rel="external">acetaminophen</a> compared outcomes among those treated with AC, AC plus GL, or no decontamination, in addition to <a class="drug drug_general" data-topicid="9317" href="/d/drug information/9317.html" rel="external">N-acetylcysteine</a>, and found no additional benefit from GL beyond that provided by AC alone [<a href="#rid27">27</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a volunteer study comparing GL administered with AC versus administration of AC alone, no statistically significant differences in reduction of systemic absorption of <a class="drug drug_general" data-topicid="9242" href="/d/drug information/9242.html" rel="external">acetaminophen</a> were noted between the two groups [<a href="#rid52">52</a>].</p><p></p><p>These results notwithstanding, there is evidence that a small subset of patients presenting early (within one hour of ingestion) may benefit from GL. In a randomized controlled trial comparing gastric emptying techniques (syrup of ipecac and GL) with AC, no significant differences were found between groups with respect to clinical deterioration or admission. However, subgroup analysis revealed that patients presenting within one hour of ingestion and treated with GL had a higher rate of clinical improvement than those receiving AC [<a href="#rid53">53</a>]. A second trial using the same protocol produced similar results, but the group treated with gastric emptying included more severe overdoses and when the authors controlled for this difference GL appeared to be of less benefit [<a href="#rid54">54</a>].</p><p>Gastric lavage carries significant risks, which, given its questionable clinical benefit, usually outweigh arguments in favor of its use. In a randomized trial, patients treated with GL had higher rates of aspiration (9 versus 0 percent) and intubation compared to controls receiving AC [<a href="#rid23">23</a>]. These findings are consistent with numerous published case reports [<a href="#rid47">47</a>]. Esophageal and gastric perforation represents another, albeit less common, risk of GL [<a href="#rid47">47,53</a>].</p><p class="headingAnchor" id="H18993956"><span class="h2">Endoscopy/surgery</span><span class="headingEndMark"> — </span>Endoscopic or surgical removal of poisons may be indicated when a life-threatening toxin has been ingested and cannot be effectively removed by less invasive means. Examples include lethal amounts of heavy metals or pharmacobezoars refractory to whole bowel irrigation. Surgical removal is indicated in patients exhibiting toxicity following ingestion of large cocaine packets ("body packers"). In most cases, endoscopy is not recommended for the removal of illicit drug packets due to the risk of packet rupture during extraction attempts<sup> </sup>[<a href="#rid55">55</a>]. (See  <a class="medical medical_review" href="/d/html/327.html" rel="external">"Internal concealment of drugs of abuse (body packing)"</a>.)</p><p class="headingAnchor" id="H11133018"><span class="h2">Outdated treatments</span><span class="headingEndMark"> — </span>The following modalities of GI decontamination have been used in the past but are <strong>no longer routinely recommended</strong>:</p><p class="headingAnchor" id="H18993963"><span class="h3">Syrup of Ipecac</span><span class="headingEndMark"> — </span>Previously a mainstay of prehospital and emergency department management of toxic ingestions, Syrup of Ipecac (SoI)-facilitated gastric emptying is no longer recommended by the American Academy of Clinical Toxicology (AACT), the European Association of Poisons Centres and Clinical Toxicologists (EAPCCT), or the American Association of Pediatrics (AAP)<sup> </sup>[<a href="#rid56">56,57</a>]. A review of volunteer and clinical studies suggests that SoI is less effective at decreasing systemic absorption than activated charcoal (AC)<sup> </sup>[<a href="#rid14">14,58</a>], yields unpredictable and inconsistent results<sup> </sup>[<a href="#rid50">50,59,60</a>], and has an increased risk of adverse effects including delayed administration of more effective decontamination measures<sup> </sup>[<a href="#rid28">28</a>] and higher rates of aspiration<sup> </sup>[<a href="#rid61">61</a>].</p><p class="headingAnchor" id="H18993978"><span class="h3">Cathartics</span><span class="headingEndMark"> — </span>Cathartics (eg, <a class="drug drug_general" data-topicid="9580" href="/d/drug information/9580.html" rel="external">magnesium citrate</a>, <a class="drug drug_general" data-topicid="9585" href="/d/drug information/9585.html" rel="external">magnesium sulfate</a>, <a class="drug drug_general" data-topicid="9940" href="/d/drug information/9940.html" rel="external">sorbitol</a>, <a class="drug drug_general" data-topicid="9587" href="/d/drug information/9587.html" rel="external">mannitol</a>) are intended to decrease poison absorption by enhancing rectal evacuation of toxins or the poison-AC complex. The AACT and EAPCCT advise against the use of cathartics as single agent therapy. The combination of a cathartic and AC (eg, sorbitol and AC) should be used sparingly in adults, if at all, and should not be used in children. If the only available formulation of AC contains sorbitol, it may be necessary to give it to a child, but treatment must be limited to a single dose in such cases<sup> </sup>[<a href="#rid62">62</a>]. (See <a class="local">'Activated charcoal'</a> above.)</p><p>Adverse effects associated with cathartic use include increased abdominal pain, nausea, vomiting, excessive diarrhea, dehydration, and electrolyte abnormalities.</p><p class="headingAnchor" id="H18993989"><span class="h3">Dilution</span><span class="headingEndMark"> — </span>Dilution was historically recommended following the ingestion of acidic or alkaline corrosives to decrease the concentration and, thus, the tissue damage from the ingestion. This approach is problematic and we recommend that it not be performed.</p><p class="headingAnchor" id="H18994094"><span class="h1">ADDITIONAL RESOURCES</span></p><p class="headingAnchor" id="H1830176207"><span class="h2">Regional poison control centers</span><span class="headingEndMark"> — </span>Regional poison control centers in the United States are available at all times for consultation on patients with known or suspected poisoning, and who may be critically ill, require admission, or have clinical pictures that are unclear (1-800-222-1222). In addition, some hospitals have medical toxicologists available for bedside consultation. Whenever available, these are invaluable resources to help in the diagnosis and management of ingestions or overdoses. Contact information for poison centers around the world is provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/138307.html" rel="external">"Society guideline links: Regional poison control centers"</a>.)</p><p class="headingAnchor" id="H1428146796"><span class="h2">Society guideline links</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/112689.html" rel="external">"Society guideline links: General measures for acute poisoning treatment"</a> and  <a class="medical medical_society_guidelines" href="/d/html/114014.html" rel="external">"Society guideline links: Treatment of acute poisoning caused by specific agents other than drugs of abuse"</a>.)</p><p class="headingAnchor" id="H18994101"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Approach </strong>– The vast majority of adults with toxic ingestions have an uncomplicated course and recover fully with supportive care. The use of techniques to reduce absorption of poisons by gastrointestinal (GI) decontamination must be guided by the potential severity of the poisoning, the time from ingestion, and the potential risk to the patient of the interventions considered. In addition, the availability of an effective antidote substantially reduces the importance of decontamination. (See <a class="local">'Approach to gastrointestinal decontamination'</a> above.)</p><p></p><p class="bulletIndent1">While various decontamination procedures can reduce blood concentrations of some ingested poisons, there are few data demonstrating that use of these procedures reduces morbidity or mortality. A protected airway (ie, patient is alert with intact airway reflexes or is intubated) is essential prior to initiation of any GI decontamination procedure.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Activated charcoal (AC) </strong>– AC has an extensive surface area that adsorbs organic chemicals within minutes of contact, preventing GI absorption and subsequent toxicity. Patients may benefit from the administration of activated charcoal (AC) in a single dose of 1 g/kg (maximum dose 50 g), particularly if given within one to two hours of ingestion. (See <a class="local">'Activated charcoal'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Contraindications </strong>– AC should be withheld in situations where clinical benefit is not expected, including (see <a class="local">'Contraindications'</a> above):</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Nontoxic ingestions</p><p class="bulletIndent3"><span class="glyph">-</span>Patients who present when poison absorption is considered complete</p><p class="bulletIndent3"><span class="glyph">-</span>Poisons not bound by AC  (<a class="graphic graphic_table graphicRef77553" href="/d/graphic/77553.html" rel="external">table 1</a>) </p><p class="bulletIndent3"><span class="glyph">-</span>Patients whose risk of complications (eg, aspiration) is unacceptably high</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Addition of cathartic</strong> – A cathartic (eg, 1 g/kg of 70 percent <a class="drug drug_general" data-topicid="9940" href="/d/drug information/9940.html" rel="external">sorbitol</a>) may be administered with the initial dose of AC. Cathartics should not be used as monotherapy, should be avoided in children, and repeated doses are <strong>not</strong> recommended. (See <a class="local">'Administration'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Multidose activate charcoal (MDAC) </strong>– In some instances, patients may benefit from the repeated administration of AC, such as to interrupt enterohepatic recirculation or reduce absorption of extended- or delayed-release formulations. Potential indications include toxicity from the following: <a class="drug drug_general" data-topicid="9198" href="/d/drug information/9198.html" rel="external">carbamazepine</a>, <a class="drug drug_general" data-topicid="9324" href="/d/drug information/9324.html" rel="external">dapsone</a>, <a class="drug drug_general" data-topicid="9763" href="/d/drug information/9763.html" rel="external">phenobarbital</a>, <a class="drug drug_general" data-topicid="9847" href="/d/drug information/9847.html" rel="external">quinine</a>, <a class="drug drug_general" data-topicid="10281" href="/d/drug information/10281.html" rel="external">theophylline</a>, caffeine, <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a>, and <a class="drug drug_general" data-topicid="9769" href="/d/drug information/9769.html" rel="external">phenytoin</a>. (See <a class="local">'Multidose activated charcoal'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Whole bowel irrigation</strong> – This is reserved for patients who have ingested toxic foreign bodies (eg, drug packets), sustained release or enteric-coated drugs, or toxic materials not bound by AC (eg, heavy metals). (See <a class="local">'Whole bowel irrigation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Gastric lavage</strong> – This is <strong>not</strong> recommended for routine decontamination. Rarely, gastric lavage may be helpful if the patient has ingested a toxic amount of a poison and the procedure can be performed within one hour of ingestion. When performed, gastric lavage should be followed by AC administration, unless the agent ingested is not adsorbed by AC. (See <a class="local">'Gastric lavage'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Chyka PA, Seger D, Krenzelok EP, et al. Position paper: Single-dose activated charcoal. Clin Toxicol (Phila) 2005; 43:61.</a></li><li><a class="nounderline abstract_t">Position statement and practice guidelines on the use of multi-dose activated charcoal in the treatment of acute poisoning. American Academy of Clinical Toxicology; European Association of Poisons Centres and Clinical Toxicologists. J Toxicol Clin Toxicol 1999; 37:731.</a></li><li><a class="nounderline abstract_t">Thanacoody R, Caravati EM, Troutman B, et al. Position paper update: whole bowel irrigation for gastrointestinal decontamination of overdose patients. Clin Toxicol (Phila) 2015; 53:5.</a></li><li><a class="nounderline abstract_t">Hoegberg LCG, Shepherd G, Wood DM, et al. Systematic review on the use of activated charcoal for gastrointestinal decontamination following acute oral overdose. Clin Toxicol (Phila) 2021; 59:1196.</a></li><li><a class="nounderline abstract_t">Olkkola KT. Effect of charcoal-drug ratio on antidotal efficacy of oral activated charcoal in man. Br J Clin Pharmacol 1985; 19:767.</a></li><li><a class="nounderline abstract_t">West L. Innovative approaches to the administration of activated charcoal in pediatric toxic ingestions. Pediatr Nurs 1997; 23:616.</a></li><li><a class="nounderline abstract_t">Canitrot E, Turgeon AF, Moore L, et al. Effect of Taste Additives on the Palatability of Activated Charcoal: a Systematic Review. J Med Toxicol 2023; 19:268.</a></li><li><a class="nounderline abstract_t">Gwilt PR, Perrier D. Influence of "thickening" agents on the antidotal efficacy of activated charcoal. Clin Toxicol 1976; 9:89.</a></li><li><a class="nounderline abstract_t">Minocha A, Herold DA, Bruns DE, Spyker DA. Effect of activated charcoal in 70% sorbitol in healthy individuals. J Toxicol Clin Toxicol 1984-1985; 22:529.</a></li><li><a class="nounderline abstract_t">Cooper GM, Le Couteur DG, Richardson D, Buckley NA. A randomized clinical trial of activated charcoal for the routine management of oral drug overdose. QJM 2005; 98:655.</a></li><li><a class="nounderline abstract_t">Merigian KS, Blaho KE. Single-dose oral activated charcoal in the treatment of the self-poisoned patient: a prospective, randomized, controlled trial. Am J Ther 2002; 9:301.</a></li><li><a class="nounderline abstract_t">Decker WJ, Combs HF, Corby DG. Adsorption of drugs and poisons by activated charcoal. Toxicol Appl Pharmacol 1968; 13:454.</a></li><li><a class="nounderline abstract_t">Minocha A, Herold DA, Barth JT, et al. Activated charcoal in oral ethanol absorption: lack of effect in humans. J Toxicol Clin Toxicol 1986; 24:225.</a></li><li><a class="nounderline abstract_t">Neuvonen PJ, Vartiainen M, Tokola O. Comparison of activated charcoal and ipecac syrup in prevention of drug absorption. Eur J Clin Pharmacol 1983; 24:557.</a></li><li><a class="nounderline abstract_t">Neuvonen PJ, Elonen E. Effect of activated charcoal on absorption and elimination of phenobarbitone, carbamazepine and phenylbutazone in man. Eur J Clin Pharmacol 1980; 17:51.</a></li><li><a class="nounderline abstract_t">Lapatto-Reiniluoto O, Kivistö KT, Neuvonen PJ. Activated charcoal alone and followed by whole-bowel irrigation in preventing the absorption of sustained-release drugs. Clin Pharmacol Ther 2001; 70:255.</a></li><li><a class="nounderline abstract_t">Crome P, Dawling S, Braithwaite RA, et al. Effect of activated charcoal on absorption of nortriptyline. Lancet 1977; 2:1203.</a></li><li><a class="nounderline abstract_t">Tenenbein M, Cohen S, Sitar DS. Efficacy of ipecac-induced emesis, orogastric lavage, and activated charcoal for acute drug overdose. Ann Emerg Med 1987; 16:838.</a></li><li><a class="nounderline abstract_t">Green R, Grierson R, Sitar DS, Tenenbein M. How long after drug ingestion is activated charcoal still effective? J Toxicol Clin Toxicol 2001; 39:601.</a></li><li><a class="nounderline abstract_t">Yeates PJ, Thomas SH. Effectiveness of delayed activated charcoal administration in simulated paracetamol (acetaminophen) overdose. Br J Clin Pharmacol 2000; 49:11.</a></li><li><a class="nounderline abstract_t">Sato RL, Wong JJ, Sumida SM, et al. Efficacy of superactivated charcoal administered late (3 hours) after acetaminophen overdose. Am J Emerg Med 2003; 21:189.</a></li><li><a class="nounderline abstract_t">Ollier E, Hodin S, Lanoiselée J, et al. Effect of Activated Charcoal on Rivaroxaban Complex Absorption. Clin Pharmacokinet 2017; 56:793.</a></li><li><a class="nounderline abstract_t">Merigian KS, Woodard M, Hedges JR, et al. Prospective evaluation of gastric emptying in the self-poisoned patient. Am J Emerg Med 1990; 8:479.</a></li><li><a class="nounderline abstract_t">Hultén BA, Adams R, Askenasi R, et al. Activated charcoal in tricyclic antidepressant poisoning. Hum Toxicol 1988; 7:307.</a></li><li><a class="nounderline abstract_t">Spiller HA, Winter ML, Klein-Schwartz W, Bangh SA. Efficacy of activated charcoal administered more than four hours after acetaminophen overdose. J Emerg Med 2006; 30:1.</a></li><li><a class="nounderline abstract_t">Chiew AL, Isbister GK, Kirby KA, et al. Massive paracetamol overdose: an observational study of the effect of activated charcoal and increased acetylcysteine dose (ATOM-2). Clin Toxicol (Phila) 2017; 55:1055.</a></li><li><a class="nounderline abstract_t">Buckley NA, Whyte IM, O'Connell DL, Dawson AH. Activated charcoal reduces the need for N-acetylcysteine treatment after acetaminophen (paracetamol) overdose. J Toxicol Clin Toxicol 1999; 37:753.</a></li><li><a class="nounderline abstract_t">Kornberg AE, Dolgin J. Pediatric ingestions: charcoal alone versus ipecac and charcoal. Ann Emerg Med 1991; 20:648.</a></li><li><a class="nounderline abstract_t">Harchelroad F, Cottington E, Krenzelok EP. Gastrointestinal transit times of a charcoal/sorbitol slurry in overdose patients. J Toxicol Clin Toxicol 1989; 27:91.</a></li><li><a class="nounderline abstract_t">Isbister GK, Downes F, Sibbritt D, et al. Aspiration pneumonitis in an overdose population: frequency, predictors, and outcomes. Crit Care Med 2004; 32:88.</a></li><li><a class="nounderline abstract_t">Moll J, Kerns W 2nd, Tomaszewski C, Rose R. Incidence of aspiration pneumonia in intubated patients receiving activated charcoal. J Emerg Med 1999; 17:279.</a></li><li><a class="nounderline abstract_t">Ilkhanipour K, Yealy DM, Krenzelok EP. The comparative efficacy of various multiple-dose activated charcoal regimens. Am J Emerg Med 1992; 10:298.</a></li><li><a class="nounderline abstract_t">Mauro LS, Mauro VF, Brown DL, Somani P. Enhancement of phenytoin elimination by multiple-dose activated charcoal. Ann Emerg Med 1987; 16:1132.</a></li><li><a class="nounderline abstract_t">Park GD, Goldberg MJ, Spector R, et al. The effects of activated charcoal on digoxin and digitoxin clearance. Drug Intell Clin Pharm 1985; 19:937.</a></li><li><a class="nounderline abstract_t">Neuvonen PJ, Elonen E, Mattila MJ. Oral activated charcoal and dapsone elimination. Clin Pharmacol Ther 1980; 27:823.</a></li><li><a class="nounderline abstract_t">Skinner CG, Chang AS, Matthews AS, et al. Randomized controlled study on the use of multiple-dose activated charcoal in patients with supratherapeutic phenytoin levels. Clin Toxicol (Phila) 2012; 50:764.</a></li><li><a class="nounderline abstract_t">Eddleston M, Juszczak E, Buckley NA, et al. Study protocol: a randomised controlled trial of multiple and single dose activated charcoal for acute self-poisoning. BMC Emerg Med 2007; 7:2.</a></li><li><a class="nounderline abstract_t">de Silva HA, Fonseka MM, Pathmeswaran A, et al. Multiple-dose activated charcoal for treatment of yellow oleander poisoning: a single-blind, randomised, placebo-controlled trial. Lancet 2003; 361:1935.</a></li><li><a class="nounderline abstract_t">Atkinson SW, Young Y, Trotter GA. Treatment with activated charcoal complicated by gastrointestinal obstruction requiring surgery. BMJ 1992; 305:563.</a></li><li><a class="nounderline abstract_t">Goulbourne KB, Cisek JE. Small-bowel obstruction secondary to activated charcoal and adhesions. Ann Emerg Med 1994; 24:108.</a></li><li><a class="nounderline abstract_t">Gomez HF, Brent JA, Munoz DC 4th, et al. Charcoal stercolith with intestinal perforation in a patient treated for amitriptyline ingestion. J Emerg Med 1994; 12:57.</a></li><li><a class="nounderline abstract_t">Position paper: whole bowel irrigation. J Toxicol Clin Toxicol 2004; 42:843.</a></li><li><a class="nounderline abstract_t">Nordt SP, Won KJ, Tomaszweski C, Clark RF. Polyethylene glycol electrolyte lavage solution increases tablet dissolution of acetaminophen in an in vitro model mimicking acute poisoning. Am J Emerg Med 2020; 38:325.</a></li><li><a class="nounderline abstract_t">Ly BT, Schneir AB, Clark RF. Effect of whole bowel irrigation on the pharmacokinetics of an acetaminophen formulation and progression of radiopaque markers through the gastrointestinal tract. Ann Emerg Med 2004; 43:189.</a></li><li><a class="nounderline abstract_t">Bretaudeau Deguigne M, Hamel JF, Boels D, Harry P. Lithium poisoning: the value of early digestive tract decontamination. Clin Toxicol (Phila) 2013; 51:243.</a></li><li><a class="nounderline abstract_t">Kumar VV, Oscarsson S, Friberg LE, et al. The effect of decontamination procedures on the pharmacokinetics of venlafaxine in overdose. Clin Pharmacol Ther 2009; 86:403.</a></li><li><a class="nounderline abstract_t">Benson BE, Hoppu K, Troutman WG, et al. Position paper update: gastric lavage for gastrointestinal decontamination. Clin Toxicol (Phila) 2013; 51:140.</a></li><li><a class="nounderline abstract_t">Hoffman RM, Maskell KF, Cumpston KL. A local survey of gastric lavage for gastrointestinal decontamination in a new century: The future marches on. Am J Emerg Med 2018; 36:1114.</a></li><li><a class="nounderline abstract_t">Saetta JP, March S, Gaunt ME, Quinton DN. Gastric emptying procedures in the self-poisoned patient: are we forcing gastric content beyond the pylorus? J R Soc Med 1991; 84:274.</a></li><li><a class="nounderline abstract_t">Saetta JP, Quinton DN. Residual gastric content after gastric lavage and ipecacuanha-induced emesis in self-poisoned patients: an endoscopic study. J R Soc Med 1991; 84:35.</a></li><li><a class="nounderline abstract_t">Tandberg D, Diven BG, McLeod JW. Ipecac-induced emesis versus gastric lavage: a controlled study in normal adults. Am J Emerg Med 1986; 4:205.</a></li><li><a class="nounderline abstract_t">Christophersen AB, Levin D, Hoegberg LC, et al. Activated charcoal alone or after gastric lavage: a simulated large paracetamol intoxication. Br J Clin Pharmacol 2002; 53:312.</a></li><li><a class="nounderline abstract_t">Kulig K, Bar-Or D, Cantrill SV, et al. Management of acutely poisoned patients without gastric emptying. Ann Emerg Med 1985; 14:562.</a></li><li><a class="nounderline abstract_t">Pond SM, Lewis-Driver DJ, Williams GM, et al. Gastric emptying in acute overdose: a prospective randomised controlled trial. Med J Aust 1995; 163:345.</a></li><li><a class="nounderline abstract_t">Trent MS, Kim U. Cocaine packet ingestion. Surgical or medical management? Arch Surg 1987; 122:1179.</a></li><li><a class="nounderline abstract_t">Höjer J, Troutman WG, Hoppu K, et al. Position paper update: ipecac syrup for gastrointestinal decontamination. Clin Toxicol (Phila) 2013; 51:134.</a></li><li><a class="nounderline abstract_t">American Academy of Pediatrics Committee on Injury, Violence, and Poison Prevention. Poison treatment in the home. American Academy of Pediatrics Committee on Injury, Violence, and Poison Prevention. Pediatrics 2003; 112:1182.</a></li><li><a class="nounderline abstract_t">Curtis RA, Barone J, Giacona N. Efficacy of ipecac and activated charcoal/cathartic. Prevention of salicylate absorption in a simulated overdose. Arch Intern Med 1984; 144:48.</a></li><li><a class="nounderline abstract_t">Auerbach PS, Osterloh J, Braun O, et al. Efficacy of gastric emptying: gastric lavage versus emesis induced with ipecac. Ann Emerg Med 1986; 15:692.</a></li><li><a class="nounderline abstract_t">Tandberg D, Wood DA. Ipecac-induced emesis and gastric lavage are equally unpleasant. Vet Hum Toxicol 1988; 30:109.</a></li><li><a class="nounderline abstract_t">Albertson TE, Derlet RW, Foulke GE, et al. Superiority of activated charcoal alone compared with ipecac and activated charcoal in the treatment of acute toxic ingestions. Ann Emerg Med 1989; 18:56.</a></li><li><a class="nounderline abstract_t">Position paper: cathartics. J Toxicol Clin Toxicol 2004; 42:243.</a></li></ol></div><div id="topicVersionRevision">Topic 321 Version 33.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15822758" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Position paper: Single-dose activated charcoal.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10584586" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Position statement and practice guidelines on the use of multi-dose activated charcoal in the treatment of acute poisoning. American Academy of Clinical Toxicology; European Association of Poisons Centres and Clinical Toxicologists.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25511637" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Position paper update: whole bowel irrigation for gastrointestinal decontamination of overdose patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34424785" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Systematic review on the use of activated charcoal for gastrointestinal decontamination following acute oral overdose.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4027120" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Effect of charcoal-drug ratio on antidotal efficacy of oral activated charcoal in man.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9429522" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Innovative approaches to the administration of activated charcoal in pediatric toxic ingestions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37000410" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Effect of Taste Additives on the Palatability of Activated Charcoal: a Systematic Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1277772" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Influence of "thickening" agents on the antidotal efficacy of activated charcoal.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6535845" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Effect of activated charcoal in 70% sorbitol in healthy individuals.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16040667" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : A randomized clinical trial of activated charcoal for the routine management of oral drug overdose.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12115019" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Single-dose oral activated charcoal in the treatment of the self-poisoned patient: a prospective, randomized, controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5726670" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Adsorption of drugs and poisons by activated charcoal.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3723647" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Activated charcoal in oral ethanol absorption: lack of effect in humans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6134626" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Comparison of activated charcoal and ipecac syrup in prevention of drug absorption.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7371700" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Effect of activated charcoal on absorption and elimination of phenobarbitone, carbamazepine and phenylbutazone in man.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11557913" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Activated charcoal alone and followed by whole-bowel irrigation in preventing the absorption of sustained-release drugs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/73903" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Effect of activated charcoal on absorption of nortriptyline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2887134" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Efficacy of ipecac-induced emesis, orogastric lavage, and activated charcoal for acute drug overdose.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11762668" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : How long after drug ingestion is activated charcoal still effective?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10606832" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Effectiveness of delayed activated charcoal administration in simulated paracetamol (acetaminophen) overdose.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12811710" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Efficacy of superactivated charcoal administered late (3 hours) after acetaminophen overdose.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27910037" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Effect of Activated Charcoal on Rivaroxaban Complex Absorption.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1977400" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Prospective evaluation of gastric emptying in the self-poisoned patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3410479" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Activated charcoal in tricyclic antidepressant poisoning.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16434328" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Efficacy of activated charcoal administered more than four hours after acetaminophen overdose.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28644687" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Massive paracetamol overdose: an observational study of the effect of activated charcoal and increased acetylcysteine dose (ATOM-2).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10584587" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Activated charcoal reduces the need for N-acetylcysteine treatment after acetaminophen (paracetamol) overdose.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1674842" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Pediatric ingestions: charcoal alone versus ipecac and charcoal.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2769824" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Gastrointestinal transit times of a charcoal/sorbitol slurry in overdose patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14707564" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Aspiration pneumonitis in an overdose population: frequency, predictors, and outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10195487" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Incidence of aspiration pneumonia in intubated patients receiving activated charcoal.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1616516" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : The comparative efficacy of various multiple-dose activated charcoal regimens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3662159" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Enhancement of phenytoin elimination by multiple-dose activated charcoal.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4085353" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : The effects of activated charcoal on digoxin and digitoxin clearance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7379451" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Oral activated charcoal and dapsone elimination.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22897408" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Randomized controlled study on the use of multiple-dose activated charcoal in patients with supratherapeutic phenytoin levels.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17498281" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Study protocol: a randomised controlled trial of multiple and single dose activated charcoal for acute self-poisoning.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12801736" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Multiple-dose activated charcoal for treatment of yellow oleander poisoning: a single-blind, randomised, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1393038" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Treatment with activated charcoal complicated by gastrointestinal obstruction requiring surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8010540" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Small-bowel obstruction secondary to activated charcoal and adhesions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8163807" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Charcoal stercolith with intestinal perforation in a patient treated for amitriptyline ingestion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15533024" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Position paper: whole bowel irrigation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31839515" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Polyethylene glycol electrolyte lavage solution increases tablet dissolution of acetaminophen in an in vitro model mimicking acute poisoning.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14747807" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Effect of whole bowel irrigation on the pharmacokinetics of an acetaminophen formulation and progression of radiopaque markers through the gastrointestinal tract.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23566313" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Lithium poisoning: the value of early digestive tract decontamination.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19606091" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : The effect of decontamination procedures on the pharmacokinetics of venlafaxine in overdose.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23418938" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Position paper update: gastric lavage for gastrointestinal decontamination.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29157788" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : A local survey of gastric lavage for gastrointestinal decontamination in a new century: The future marches on.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1674963" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Gastric emptying procedures in the self-poisoned patient: are we forcing gastric content beyond the pylorus?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1671603" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Residual gastric content after gastric lavage and ipecacuanha-induced emesis in self-poisoned patients: an endoscopic study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2870722" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Ipecac-induced emesis versus gastric lavage: a controlled study in normal adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11874395" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Activated charcoal alone or after gastric lavage: a simulated large paracetamol intoxication.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2859819" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Management of acutely poisoned patients without gastric emptying.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7565257" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Gastric emptying in acute overdose: a prospective randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3662800" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Cocaine packet ingestion. Surgical or medical management?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23406298" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Position paper update: ipecac syrup for gastrointestinal decontamination.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14595067" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Poison treatment in the home. American Academy of Pediatrics Committee on Injury, Violence, and Poison Prevention.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6140906" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Efficacy of ipecac and activated charcoal/cathartic. Prevention of salicylate absorption in a simulated overdose.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2871787" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Efficacy of gastric emptying: gastric lavage versus emesis induced with ipecac.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2898180" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Ipecac-induced emesis and gastric lavage are equally unpleasant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2562913" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Superiority of activated charcoal alone compared with ipecac and activated charcoal in the treatment of acute toxic ingestions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15362590" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Position paper: cathartics.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
